Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432332 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL4433801 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL31410080 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL10636302 | 0.89 | CYP2D6 (0.43) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL28264659 | 0.87 | CYP2D6 (0.43) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL156884 | 0.86 | CYP2D6 (0.50) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL9202353 | 0.84 | CYP2D6 (0.43) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL13362393 | 0.82 | CYP2D6 (0.43) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL1063303 | 0.82 | CYP2D6 (0.43) | CYP2D6CYP1A2GAAKMT2AMEN1 | |
| SCHEMBL9205825 | 0.82 | CYP2D6 (0.43) | CYP2D6CYP1A2GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2118086-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008090140-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2008-07-31 | — | — | WO | disclosed |
| EP-1947103-A1 | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments | 4SC AG (DE) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | ADRB3, ADRB1, ADRB2 | CYP2D6 168/4885CYP1A2 265/4885GAA 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.